Inventor
HOLLINGWORTH GREGORY JOHN
GB27 patents
⚠️ This page may combine multiple inventors who share the name “HOLLINGWORTH GREGORY JOHN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK SHARP & DOHME
17 patentsUS6172077B1Jan 9, 2001
Spiro-azacyclic derivatives and their use as therapeutic agents
MERCK SHARP & DOHME149 citations97
US6114315ASep 5, 2000
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
MERCK SHARP & DOHME26 citations92
US5977104ANov 2, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME29 citations92
US5952315ASep 14, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME34 citations92
US6518273B1Feb 11, 2003
2-aryl indole derivative as antagonists of tachykinins
MERCK SHARP & DOHME31 citations88
US6476045B2Nov 5, 2002
Azaindole derivatives and their use as therapeutic agents
MERCK SHARP & DOHME16 citations83
US6271230B1Aug 7, 2001
Use of NK-1 receptor antagonists for treating cognitive disorders
MERCK SHARP & DOHME6 citations74
US6071927AJun 6, 2000
Spiro-piperidine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME13 citations74
US5925627AJul 20, 1999
Use of NK-1 receptor antagonists for treating movement disorders
MERCK SHARP & DOHME7 citations74
US6100256AAug 8, 2000
Use of NK-1 receptors antagonists for treating schizophrenic disorders
MERCK SHARP & DOHME7 citations73
US6087348AJul 11, 2000
Use of NK-1 receptor antagonists for treating stress disorders
MERCK SHARP & DOHME3 citations63
US5919781AJul 6, 1999
Use of NK-1 receptor antogonists for treating substance use disorders
MERCK SHARP & DOHME5 citations63
US7105507B2Sep 12, 2006
Cyclohexane derivatives and their use as therapeutic agents
MERCK SHARP & DOHME4 citations62
US7442701B2Oct 28, 2008
Amino-heterocycles as VR-1 antagonists for treating pain
MERCK SHARP & DOHME6 citations60
US6096729AAug 1, 2000
Use of NK-1 receptor antagonists for treating amnestic disorders
MERCK SHARP & DOHME0 citations52
US6613765B1Sep 2, 2003
Use of NK-1 receptor antagonists for treating major depressive disorders
MERCK SHARP & DOHME0 citations51
US7253205B2Aug 7, 2007
Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents
MERCK SHARP & DOHME0 citations41
NOVARTIS AG
3 patentsUS11541056B2Jan 3, 2023
3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
NOVARTIS AG2 citations71
US12441733B2Oct 14, 2025
Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
NOVARTIS AG0 citations59
US11613543B2Mar 28, 2023
Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
NOVARTIS AG1 citations59
BELLENIE BENJAMIN RICHARD
3 patentsUS10112926B2Oct 30, 2018
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
BELLENIE BENJAMIN RICHARD1 citations47
US9862711B2Jan 9, 2018
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BELLENIE BENJAMIN RICHARD1 citations47
US10004732B2Jun 26, 2018
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BELLENIE BENJAMIN RICHARD0 citations36